CUPERTINO, Calif., Sept. 15 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global
Life Sciences Conference being held at the Grand Hyatt Hotel in New York.
Matthew J. Hogan, Chief Financial Officer, will be presenting at the
conference on September 22 at 10:30 a.m. Eastern Time.
A live audio webcast of the presentation will be available by accessing
DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.”
If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing
innovative drugs for pain and other chronic diseases, with late-stage
development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and
TRANSDUR(TM)-Sufentanil. DURECT’s proprietary oral, transdermal and
injectable depot delivery technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved convenience,
compliance, efficacy and safety for small molecule and biologic drugs. For
more information, please visit http://www.www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the US Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation
CONTACT: Matthew J. Hogan, Chief Financial Officer of DURECT
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, email@example.com
Web site: http://www.www.durect.com